Hypersensitivity. Not to be administered aimlessly for long period. Increased risk of Clostridium-difficile-associated disease (CDAD), especially in hospitalized patients; developing certain infections eg, community-acquired pneumonia; osteoporosis-related fractures of hip, wrist or spine w/ high-dose &/or prolonged period of time ie, ≥1 yr. Projectile & oozing bleeding or at risk for rapid bleeding eg, presence of exposed blood vessels; visual disturbance; persistent diarrhea. Symptomatic & asymptomatic hypomagnesemia in patients receiving long-term therapy (at least 3 mth, most case >1 yr of therapy). May mask symptoms of gastric cancer. Closely observe course of disease & use min therapeutic necessity according to disease condition. Switch to another treatment if the drug is ineffective. Severe hepatic impairment (Child-Pugh class C). Hepatic disorders. Women of childbearing potential. Pregnancy & lactation. Childn. Elderly.
A02BC03 - lansoprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Sign Out
